What is RARE's current stock price?

As of now, RARE is trading at $36.54, with a daily change of +0.25%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

RARE Stock Analysis & IQ Rating | Ultragenyx Pharmaceu

RARE

Ultragenyx Pharmaceu

$36.54

+$0.09 | +0.25%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$50

MKT CAP

$3.53B

52W Low

$25.81

VOL

$1.24M

P/E Ratio

N/A

AVG VOL

$1.33M

RSI

63.45

TREND

Uptrend

RARE Stock IQ

Login to see Ultragenyx Pharmaceu (RARE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

RARE Target Price

Login to display

Strengths

RARE Rewards

Upgraded on attractively valued

RARE Rewards

Earnings are forecast to grow

RARE Rewards

Investors confidence is positive

RARE Price Performance

$30.63 (+19.29%)

$31.23 (+17.00%)

$27.31 (+33.80%)

$42.94 (-14.90%)

1year

6month

3month

1month

RARE Risk Level

RARE has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

RARE Analysts Opinion

RARE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

RARE Analysts Opinion

RARE Analysts opinion is positive and also has improved from the past 3 months

RARE Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

92%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

RARE Street Sentiment

RARE Street Sentiment is extremely bullish and have positive views on the near-term outlook

RARE Performance Sentiment

Sentiments overview associated with RARE events and the stock performance.

92%

8%

Positive

Negative

11 out of 12
events present

1 out of 12
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$36.45

Resistance
Price

$30.63

Current Price Range

$36.45

Show methods +

Linked to RARE

IQ

Close Price

Change

MREO

3.50

2.04

+4.08%

RARE Latest Analysis +

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence Strong Uptake of New Drugs and Emergence of High-cost Gene Therapies | DelveInsight. The dynamics of the hemophilia A market are expected to change mainly due to the increase in prevalence and the launch of upcoming therapies such as Mim8 (Novo Nordisk) DTX201 (Pebocotocogene camaparvovec BAY2599023 [Ultragenyx Pharmaceutical]) giroctocogene fitelparvovec (SB-5

Wed Dec 3, 2025

$36.45 | +8.90%

Activity

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Wed Dec 3, 2025

$36.45 | +8.90%

Activity

Ultragenyx Pharmaceutical Breaks Above 200-Day Moving Average - ish for RARE. In trading on Friday shares of Ultragenyx Pharmaceutical Inc (Symbol: RARE) crossed above their 200 day moving average of $34.15 changing hands as high as $34.36 per share. Ultragenyx Pharmaceutical Inc shares are currently trading up about 1.4% on the day. The chart below s

Fri Nov 28, 2025

$34.75 | +2.93%

Momentum

Technical

Barclays Remains Cautious on Ultragenyx (RARE) Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks with huge upside potential. On November 24 Barclays analyst Gena Wang lowered the firms price target on Ultragenyx (RARE) to $50 from $81 and maintained an Overweight rating on the shares. The firm lowered its price target following analysis of the setrusumab COSMIC study but [….]

Fri Nov 28, 2025

$34.75 | +2.93%

Activity

Potential

Rating

Barclays Maintains Ultragenyx Pharmaceutical (RARE) Overweight Recommendation. Fintel reports that on November 24 2025 Barclays maintained coverage of Ultragenyx Pharmaceutical (NasdaqGS:RARE) with a Overweight recommendation. Analyst Price Forecast Suggests 148.20% Upside

Tue Nov 25, 2025

$33.53 | +2.27%

Rating

Ultragenyx to Participate in Investor Conferences in December. NOVATO Calif. Nov. 24 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases today announced participation in two upcoming investor conferences.

Mon Nov 24, 2025

$32.78 | -2.41%

Activity

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). NOVATO Calif. Nov. 21 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases today reported the grant of 18180 restricted stock units of the companys common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the

Fri Nov 21, 2025

$33.59 | +7.73%

Activity

FAQ About RARE Stock Insights

What is RARE current stock price?

What are RARE stock strengths?

What is RARE Risk Level?

What is RARE market cap and volume?

What is RARE current Stock IQ?

Should I buy RARE stock right now?

Is RARE a Strong Buy right now?

What does a 'Strong Buy' rating mean for RARE?

What does a 'Strong Sell' rating mean for RARE?

What factors influence RARE's Stock IQ?

Explore our RARE Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored RARE Stock Strategies
Effective Risk Management

FIND US ON

Receive our RARE Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

RARE

Ultragenyx Pharmaceu

Current Price

$36.54

+$0.09 | +0.25%

52W High

$50

MKT CAP

$3.53B

52W Low

$25.81

VOL

$1.24M

P/E Ratio

N/A

AVG VOL

$1.33M

RSI

63.45

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

RARE Rewards

Upgraded on attractively valued

RARE Rewards

Earnings are forecast to grow

RARE Rewards

Investors confidence is positive

Linked to RARE

Symbol

IQ

Close

Change

MREO

3.50

2.04

+4.08%

RARE Price Performance

$30.63 (+19.29%)

$31.23 (+17.00%)

$27.31 (+33.80%)

$42.94 (-14.90%)

1year

6month

3month

1month

RARE Analysts Opinion

RARE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

RARE Analysts Opinion

RARE Analysts opinion is positive and also has improved from the past 3 months

RARE Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

92%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

RARE Street Sentiment

RARE Street Sentiment is extremely bullish and have positive views on the near-term outlook

RARE Risk Level

RARE has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

RARE Performance Sentiment

Sentiments overview associated with RARE events and the stock performance.

92%

8%

Positive

Negative

11 out of 12
events present

1 out of 12
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$36.45

Resistance
Price

$30.63

Current Price Range

$36.45

Show methods +

RARE Stock IQ

Login to unlock Ultragenyx Pharmaceu (RARE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

RARE Latest Analysis

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence Strong Uptake of New Drugs and Emergence of High-cost Gene Therapies | DelveInsight. The dynamics of the hemophilia A market are expected to change mainly due to the increase in prevalence and the launch of upcoming therapies such as Mim8 (Novo Nordisk) DTX201 (Pebocotocogene camaparvovec BAY2599023 [Ultragenyx Pharmaceutical]) giroctocogene fitelparvovec (SB-5

Wed Dec 3, 2025

$36.45 | +8.90%

Activity

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Wed Dec 3, 2025

$36.45 | +8.90%

Activity

Ultragenyx Pharmaceutical Breaks Above 200-Day Moving Average - ish for RARE. In trading on Friday shares of Ultragenyx Pharmaceutical Inc (Symbol: RARE) crossed above their 200 day moving average of $34.15 changing hands as high as $34.36 per share. Ultragenyx Pharmaceutical Inc shares are currently trading up about 1.4% on the day. The chart below s

Fri Nov 28, 2025

$34.75 | +2.93%

Momentum

Technical

Barclays Remains Cautious on Ultragenyx (RARE) Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks with huge upside potential. On November 24 Barclays analyst Gena Wang lowered the firms price target on Ultragenyx (RARE) to $50 from $81 and maintained an Overweight rating on the shares. The firm lowered its price target following analysis of the setrusumab COSMIC study but [….]

Fri Nov 28, 2025

$34.75 | +2.93%

Activity

Potential

Rating

Barclays Maintains Ultragenyx Pharmaceutical (RARE) Overweight Recommendation. Fintel reports that on November 24 2025 Barclays maintained coverage of Ultragenyx Pharmaceutical (NasdaqGS:RARE) with a Overweight recommendation. Analyst Price Forecast Suggests 148.20% Upside

Tue Nov 25, 2025

$33.53 | +2.27%

Rating

Ultragenyx to Participate in Investor Conferences in December. NOVATO Calif. Nov. 24 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases today announced participation in two upcoming investor conferences.

Mon Nov 24, 2025

$32.78 | -2.41%

Activity

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). NOVATO Calif. Nov. 21 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases today reported the grant of 18180 restricted stock units of the companys common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the

Fri Nov 21, 2025

$33.59 | +7.73%

Activity

Discover RARE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of RARE. We're here to help you make informed investment decisions today.

FIND US ON

Receive our RARE Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

RARE Stock trends

RARE Stock performance

RARE Stock analysis

RARE investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing RARE

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing RARE

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

RARE Stock Analysis & IQ Rating | Ultragenyx Pharmaceu

RARE Stock IQ

RARE Target Price

RARE Risk Level

RARE Analysts Opinion

RARE Street Sentiment

RARE Performance Sentiment

Technical Price Levels

Explore our RARE Stock insights

Receive our RARE Daily Alerts

RARE Street Sentiment

RARE Risk Level

Technical Price Levels

Discover RARE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of RARE. We're here to help you make informed investment decisions today.

Receive our RARE Daily Alerts

RARE Runner Alarm